01—Abstract
Summary
Summary of the 10-K filed February 17, 2026. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported total revenues of $1,396.6 milliona for 2025, up from $1,015.3 million in 2024, driven primarily by royalties of $867.8 million (up from $571.0 million) and product sales, net of $376.4 million.
Revenues under collaborative agreements were $152.3 millionb. Operating income fell to $469.0 million from $551.5 million, reflecting $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition, a $48.7 million impairment of the ATRS-1902 intangible asset, and higher cost of sales and SG&A. Net income was $316.9 million, or $2.56 per diluted share, compared with $444.1 million, or $3.43, in 2024.
Royalty growth was led by DARZALEX SC, VYVGART Hytrulo and Phesgo, and the company said ENHANZE remains its largest revenue driver. The company significantly expanded its balance sheet during the year. It acquired Elektrofi (later renamed Halozyme Hypercon, Inc.) for total consideration of $810.4 millionc and Surf Bio for $305.0 million, plus up to $100.0 million in contingent milestones.
In November 2025 it issued $750.0 milliond of 0.00% Convertible Notes due 2031 and $750.0 million of 0.875% Convertible Notes due 2032, and used proceeds to repurchase portions of its 2027 and 2028 Convertible Notes. Total long-term debt carrying value was $2,142.6 million at year-end, against cash, cash equivalents and marketable securities of $142.8 million. Stockholders' equity fell to $48.8 million from $363.8 million, largely due to share repurchases and capped call purchases recorded in equity.
Management states that current cash and marketable securities are sufficient for at least the next 12 months, and the $750.0 million revolving credit facility was undrawn at year-end. Key risks highlighted in the filing include dependence on partner performance and regulatory approvals, reliance on rHuPH20 supply from contract manufacturers, product liability exposure, a patent infringement lawsuit against Merck over MDASE technology, U.S. drug pricing and tariff policy, and the potential dilution and cash settlement obligations of the convertible notes.
02—Key points
Key Highlights
- Total revenues rose to $1,396.6 million in 2025 from $1,015.3 million in 2024, with royalties of $867.8 million (up from $571.0 million) the largest component.
- Net income declined to $316.9 million ($2.56 diluted EPS) from $444.1 million ($3.43 diluted EPS), mainly due to $284.9 million of acquired IPR&D expense and a $48.7 million intangible impairment.
- Operating expenses more than doubled to $927.6 million from $463.8 million, including higher cost of sales ($228.8 million) and SG&A ($207.1 million).
- Acquisitions of Elektrofi ($810.4 million total consideration) and Surf Bio ($305.0 million) expanded the Hypercon and Surf Bio drug delivery technology portfolios.
- Total long-term debt carrying value reached $2,142.6 million after issuing $1.5 billion of 2031 and 2032 Convertible Notes, against cash, equivalents and marketable securities of $142.8 million.
- Stockholders' equity decreased to $48.8 million from $363.8 million, reflecting share repurchases totaling $342.4 million in cash in 2025 and capped call transactions recorded in equity.
- Halozyme filed a patent infringement lawsuit against Merck in April 2025 alleging SC Keytruda uses its MDASE technology, and a German court granted a preliminary injunction in December 2025.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2025, Halozyme Therapeutics kept $0.23.
- Revenue$1.40B100.0%
- Cost of revenue−$228.8M16.4%
- Gross profit$1.17B83.6%
- Operating costs−$698.8M50.0%
- Operating income$469.0M33.6%
- Interest, other & tax−$152.1M10.9%
- Net income$316.9M22.7%
Where FY2025 revenue went
$1.40B- Other operating costs: $491.7M, 35% of revenue
- Net income: $316.9M, 23% of revenue
- Cost of revenue: $228.8M, 16% of revenue
- SG&A: $207.1M, 15% of revenue
- Interest, other & tax: $152.1M, 11% of revenue
Kept 23% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2025filed February 17, 2026Financial Statements
FY2025 against FY2024
| Line item | FY2025FY2024 | Change |
|---|---|---|
| Revenue | $1.40B$1.02B | +37.6% |
| Cost of Revenue | $228.77M$159.42M | +43.5% |
| Gross Profit | $1.17B$855.91M | +36.4% |
| SG&A Expenses | $207.09M$154.34M | +34.2% |
| Operating Expenses | $927.61M$463.85M | +100.0% |
| Operating Income | $469.01M$551.48M | −15.0% |
| Net Income | $316.89M$444.09M | −28.6% |
| EPS (Basic) | $2.64$3.50 | −24.6% |
| EPS (Diluted) | $2.56$3.43 | −25.4% |
| Shares Outstanding (Basic) | 119.84M126.83M | −5.5% |
| Shares Outstanding (Diluted) | 123.90M129.42M | −4.3% |
05—Questions
Frequently Asked Questions
How much of the 2025 revenue came from royalties, and which partner products drove the growth?
Royalties were $867.8 million in 2025, up 52% from $571.0 million in 2024. The filing attributes the increase primarily to DARZALEX SC by Janssen, VYVGART Hytrulo by argenx and Phesgo by Roche, with royalties from VYVGART Hytrulo rising to $157.2 million from $28.9 million.
Why did operating income and net income decline in 2025 despite higher revenue?
Operating income fell to $469.0 million from $551.5 million because of $284.9 million of acquired in-process R&D expense related to the Surf Bio acquisition, a $48.7 million impairment of the ATRS-1902 intangible asset, and higher cost of sales and SG&A. The filing also notes a higher income tax expense of $150.0 million, partly driven by non-deductible acquired IPR&D.
What is the company's liquidity position and debt profile at year-end 2025?
Cash, cash equivalents and marketable securities totaled $142.8 million at December 31, 2025. Long-term debt carrying value was $2,142.6 million, against aggregate convertible note principal of $2,179.6 million. The $750.0 million revolving credit facility was undrawn, and management believes current resources will fund operations for at least the next 12 months.
What are the main risks to the business highlighted in the filing?
Key risks include failure or delay of regulatory approvals for partnered and proprietary products, reliance on partners to develop and commercialize products, dependence on rHuPH20 supply from third-party manufacturers, possible adverse events or recalls, product liability exposure, U.S. drug pricing and tariff policy changes, and the dilution or cash settlement obligations of the convertible notes.
What share repurchase activity occurred in 2025?
The company repurchased 6,996,305 shares in 2025 at a weighted-average price of $52.42, totaling $366.8 million, including the $250.0 million accelerated share repurchase completed in March 2025. As of December 31, 2025, $157.6 million remained available under the February 2024 $750.0 million program.
06—Continue